Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALA-3000
- Development stage
- Phase 1
- Lead developer
- Alar Pharmaceuticals
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
ALA-3000 is a proprietary, extended-release injectable formulation of ketamine developed by Alar Pharmaceuticals for the treatment of treatment-resistant depression (TRD). It utilizes the company's In-Relar sustained release drug delivery platform to provide a long-acting effect, maintaining therapeutic levels of ketamine in the blood for over one week following a single subcutaneous dose. This approach aims to deliver stable antidepressant effects while reducing side effects commonly associated with rapid-acting ketamine formulations, such as sedation and dissociation. The drug is currently being evaluated in Phase 1 clinical trials in the United States to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with TRD[1][2][3][4][6]. Preclinical studies have demonstrated prolonged antidepressant effects lasting more than one month in animal models[6].
- Other names
- Depot ketamine formulation - Alar Pharmaceuticalsketamine depot
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)AMPAR (AMPA receptor)DRD (Dopamine receptors)Nicotinic Acetylcholine ReceptorMOR (Mu opioid receptor)
Beyond the preview
Go deeper on ALA-3000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALA-3000.